MedTrace Logo

Aurora Test for Patients Treated With Recombinant Gonadotropins

NCT04710264 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 137

Last updated 2025-09-08

No results posted yet for this study

Summary

This is an observational study. The main aim is to determine the expression of potential biomarker genes in the cumulus cells isolated from individual oocytes in two patient cohorts: recombinant human Follicle Stimulating Hormone(hFSH) and recombinant hFSH:human Luteinizing Hormone(r-hLH) ratio 2:1. Algorithms from gene combinations will be identified that predict embryo quality and pregnancy outcomes.

Conditions

Interventions

OTHER

AURORA-Rec

Explorative study of cumulus cells gene expression in relation to the patient treatment and oocyte competence.

Sponsors & Collaborators

  • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany

    collaborator INDUSTRY

  • Fertiga, Belgium

    lead INDUSTRY

Eligibility

Min Age
22 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-02-15
Primary Completion
2023-12-31
Completion
2025-09-01

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04710264 on ClinicalTrials.gov